Trial results

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

NCT06388187 on ClinicalTrials.gov · last registry update 2026-05-05

Finished 22 April 2026, after enrolling 300 people. Primary outcome, as filed: Relative change in body weight. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

300

Started

2024-06-24

Primary completion

2026-04-22 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative change in body weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.